Safety and clinical efficacy of immune checkpoint inhibitors in pediatric hepatocellular carcinoma: a case report and review of the literature [0.03%]
免疫检查点抑制剂治疗儿童肝细胞癌的安全性和临床疗效：1例报告及文献复习
Xiaoting Zhong,Xuejiao Wen,Xinping Wang et al.
Xiaoting Zhong et al.
Background: Pediatric hepatocellular carcinoma (HCC) is rare, with surgical resection and liver transplantation as primary treatments. No standard options exist for unresectable/metastatic disease. Although immune checkpo...
Broad-spectrum antitumor analysis of the telomerase activity inhibitor TPCH derived from the human constitutively expressed protein LPTS/PinX1 [0.03%]
来源于人组成型表达蛋白LPTS / PinX1的端粒酶活性抑制剂TPCH的广谱抗肿瘤分析
Hongchang Zhou,Xiaoying Zhang,Yao Wang et al.
Hongchang Zhou et al.
Background: The human liver-related putative tumor suppressor LPTS/PinX1 is a gene encoding a telomerase inhibitory protein. Overexpression of LPTS/PinX1 protein can inhibit the growth of multiple telomerase-positive canc...
Clinical decision-making for uveal melanoma radiotherapy: comparative performance of experienced radiation oncologists and leading generative AI models [0.03%]
眼脉络膜黑色素瘤放射治疗的临床决策：经验丰富的放射肿瘤学家与领先生成式AI模型的比较性能分析
Xing Wang,Peng Wang
Xing Wang
Background: Uveal melanoma is the most common primary intraocular malignancy in adults, yet radiotherapy decision-making for this disease often remains complex and variable. Although emerging generative AI models have sho...
Multi-analyte liquid biopsy approaches for early detection of esophageal cancer: the expanding role of ctDNA [0.03%]
基于ctDNA的多指标液体活检技术在食管癌早期检测中的应用及前景展望
Derek Tai,Kareem Latif,Pranati Shah et al.
Derek Tai et al.
Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for the early detection of esophageal cancer (EC), offering a minimally invasive means to assess tumor-derived genomic and epigenomic alterations. This review synthesizes cu...
Marta Tripepi,Ana G da Costa,Dennis S Chi et al.
Marta Tripepi et al.
Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare and highly aggressive ovarian neoplasm, predominantly affecting young women, often in their second or third decade of life. Despite its distinctive clinical and pathol...
Analysis of survival differences in advanced triple-negative breast cancer: a real-world study [0.03%]
一项关于晚期三阴性乳腺癌生存差异的现实世界研究分析
Jun-Sheng Zheng,Xiao-Wen Wang,Zhi-Qiang Shi et al.
Jun-Sheng Zheng et al.
Background: Advanced triple-negative breast cancer (aTNBC) has a poor prognosis, and there is a dearth of relevant real-world research data. This study is aimed at analyzing the survival outcomes and subgroup characterist...
Case Report: A rare hyperplastic polyp with synchronous high-grade intraepithelial neoplasia in both glandular and squamous epithelium in autoimmune gastritis [0.03%]
自身免疫性胃炎并存腺上皮和鳞状上皮高级别上皮内瘤变的罕见增生性息肉1例
Dian Zhang,Xueqin Chen,Maher Hendi et al.
Dian Zhang et al.
A 68-year-old man came to evaluate a gastric polyp discovered during a routine gastroscopy. After endoscopic mucosal resection, pathological findings confirmed that it's a hyperplastic polyp. Notably, squamous metaplasia was observed within...
PNI as a predictive biomarker: a novel nomogram of immunotherapy efficacy in advanced breast cancer [0.03%]
预测生物标志物的PNI：晚期乳腺癌免疫治疗疗效的新列线图模型
Xinyang Li,Xiang Cheng,Yikai Han et al.
Xinyang Li et al.
Purpose: There has been a persistent upward trend in breast cancer (BC) incidence in recent years. The advancement of immunotherapy has introduced promising therapeutic options. This study focuses on identify potential bi...
CD70 as a target in cancer immunotherapy: advances, challenges, and future directions [0.03%]
CD70在癌症免疫治疗中的作用：进展、挑战与未来方向
Ruchen Wu,Junze Chen,Gang Wang et al.
Ruchen Wu et al.
Cancer immunotherapy represents a paradigm shift in oncology by leveraging the immune system to target tumors. The therapeutic efficacy of these approaches depends critically on identifying molecular targets that enhance treatment responses...
Real-world effectiveness and safety of CDK4/6i in elderly and BIPOC patients with HR+/HER2- advanced/metastatic breast cancer: an updated systematic literature review [0.03%]
cyclin依赖性激酶4和6抑制剂在老年和BIPOC人种HR阳性/HER2阴性晚期或转移性乳腺癌患者中的疗效和安全性：一项系统文献回顾的更新版
Nadia Harbeck,Adam Brufsky,Chloe Grace Rose et al.
Nadia Harbeck et al.
Background and aim: The HR-positive/HER2-negative (HR+/HER2-) advanced/metastatic breast cancer (a/mBC) treatment landscape has advanced with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), yet outcome disparities persi...